top of page

Our Vectors

Our Vector in a Nutshell
Our Vector table.png



- Since the beginning of gene therapies, there has been a debate of which vector type is more effective in transporting DNA into a cell. The two main “camps” are: viral and non-viral vectors, each with their advantages & disadvantages (see table left)

Our value-add: We have taken the non-viral vector approach and attempted to improve it’s main weaknesses. Our vector prioritizes safety and contains four innovative properties:

  1. Improved safety of gene therapy due to absence of antibiotic resistance genes

  2. Absence of any virus elements in the construction, ensuring further safety

  3. Smaller length of vector ensuring a more efficient gene delivery

  4. Producibility and constructability on an industrial scale

The Vector Development

Our non-viral DNA vector VTvaf17 has already:


  • Filed a separate patent protecting its own IP

  • Successfully completed toxicology tests, proving its safety and low side effect risk

  • Deposited the strains in an international depository in accordance with Budapest Treaty of 1977

  • And is a vehicle that can be used to delivery any gene combinations

Strains used for the Vector Development:

  • Strain Escherichia coli SCS 110-AF was utilized for the development of the vectors on its base, bearing the section coding the human's target gene(s), and not containing antibiotic resistance genes

  • This complies with strict requirements of regulators relating to therapeutic safety of medicinal products 


RU 2 678 756, International Application Number: РСТ/RU2018/000191, WO2019/039962, USA Application Number: 16636713; Title of Invention: “Gene therapy DNAvector VTvaf17, production method, strain Escherichia coli SCS110-AF, production method, strain Escherichia coli SCS110-AF/ VTvaf17, bearing gene therapy DNA-vector VTvaf17, production method”. Date of invention: 25.08.2017.


More information about patents:

Apart from that, at present we are ready to additionally offer other gene therapy vectors developed and patented by the group of our companies   within the frames of this concept (the absence of viral genomes and antibiotic resistance genes the DNA-vectors):

  • gene therapy vector VTvaf17-Cas9 for realization of various methods of genome editing of human and animal cells;

  • gene therapy vector VTvaf17-Act1-Cas9 for realization of various methods of genome editing of plant cells;

  • gene therapy vector GDTT1.8NAS12, 2591 bp in size (close to VTvaf17 platform solution);

  • eleven gene therapy vectors GDTT1.8NAS1, GDTT1.8NAS2, GDTT1.8NAS3, GDTT1.8NAS4, GDTT1.8NAS5, GDTT1.8NAS6, GDTT1.8NAS7, GDTT1.8NAS8, GDTT1.8NAS9, GDTT1.8NAS10, GDTT1.8NAS11 for tissue-specific expression of target genes (in muscular tissue, skin, vascular endothelium, bone tissue, bronchi and pulmonary alveoli epithelium, nerve tissue, kidney (podocytes), blood (hemopoietic cells of blood or lymphocytes or macrophages), pancreatic gland (beta cells of pancreas).

Our Licensing Service:


We offer the service of licensing out our vector to third parties at affordable rates. If you are interested in this service please contact us here

For more information, see our presentation: download here

bottom of page